Sun Pharma gets CDSCO panel nod to manufacture, and market Etifoxine HCL capsules for anxiety
New Delhi: The drug major Sun Pharmaceuticals has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) manufacture and market Etifoxine HCl Capsule 50 mg for generalized anxiety disorder with somatic symptoms.
In addition to the above, the expert panel suggested the firm conduct the post-marketing surveillance (PMS) study with the primary objective of evaluating the drug dependence of Indian subjects.
This came after the drug major Sun Pharmaceuticals presented a Phase-III clinical trial report of the drug Etifoxine HCl Capsule 50 mg for grant of manufacture and market permission in the country.
Etifoxine is a benzoxazine class drug primarily used as an anxiolytic, but that also possesses neuroprotective, neuroplastic, and anti-inflammatory properties; these effects are thought to arise due to modulation of GABAergic neurotransmission and neurosteroid synthesis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.